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Introduction {#sec005}
============

China had the largest diabetes epidemic in the world, and the prevalence continued to increase \[[@pone.0223769.ref001]\]. According to national surveys, the prevalence of diabetes in China was 0.9% in 1980, and it became 2.5% in 1994 and 2.6% in 2002 \[[@pone.0223769.ref002]\]. Furthermore, based on the data from the most recent national survey in 2013, the estimated prevalence of diabetes increased sharply to 10.9% \[[@pone.0223769.ref003]\], representing an estimated 148.3 million population with diabetes. Although an additional diagnostic criterion HbA~1c~ (glycated hemoglobinA~1c~, concentration of 6.5% or higher) was included after 2010, these data documented a rapid increase in diabetes in China. Diabetes have become a major public health problem for Chinese population.

The prevalence of diabetes raised a serious social economic concern. Because of the disorder of glucose metabolism, diabetes affected multiple organ systems and was associated with a wide range of vascular and nonvascular conditions \[[@pone.0223769.ref004]\]. Therefore, patients with diabetes tended to have huge medical expenditures and to take more medications to maintain their quality of life and longevity. One research showed that, the annual per capita medical spending for patients with diabetes was estimated to be more than twice that for patients without diabetes \[[@pone.0223769.ref005]\]. Health expenditure related to diabetes and its complications (such as periodontal disease, blindness, amputations, end-stage renal disease and cardiovascular disease, etc.) in China reached US\$51 billion in 2015, which ranked second in worldwide health expenditure \[[@pone.0223769.ref001]\]. Among the total health expenditure, medication cost represented a substantial proportion, taking 32%-62% of total expenditure in low-and middle-income countries \[[@pone.0223769.ref006]\]. In China, for general patients, the medication cost took more than 47% of the total health expenditure for outpatients and nearly 35% for inpatients in 2016 \[[@pone.0223769.ref007]\]. For patients with diabetes, this number was bigger. One research about insured Type 2 diabetes patients with chronic kidney disease under hospitalization in China showed that the medication cost accounted for more than 47% of the total cost, and among which nearly 30% were anti-diabetics \[[@pone.0223769.ref008]\]. Another research found that 17% of older adults with diabetes experienced catastrophic healthcare expenditure on medications \[[@pone.0223769.ref009]\]. The availability and affordability of anti-diabetic medicines were pivotal for patients with diabetes. As a chronic, progressive condition, diabetes required a long-term drug therapy. A cost-effective treatment available to patients with diabetes may lead to substantial reductions in morbidity and mortality \[[@pone.0223769.ref010]\]. However, according to a report, only 25.8% of Chinese patients received diabetes treatment \[[@pone.0223769.ref011]\]. One important reason for no treatment was poor availability and lack of affordability of essential medicines for diabetes \[[@pone.0223769.ref012]\].

In China, patients can obtain prescription medicines from hospitals, primary care institutions, and private pharmacies with a prescription from a physician \[[@pone.0223769.ref013]\]. Although more than 95% of Chinese people were covered by social health insurance \[[@pone.0223769.ref014]\], mostly only inpatient expenditures can be refunded. In recent years, the health insurance started to consider outpatient reimbursement for chronic diseases. However, only essential medicines purchased from specific pharmacies (usually one patient can specify two public hospitals and one private pharmacy) can be reimbursed \[[@pone.0223769.ref015]\]. In China, majority of the essential medicines were generics. Therefore, for patients with diabetes, lower availability of essential anti-diabetic generics, especially in public hospitals, meant higher out-of-pocket payment, which would make them unaffordable.

Several studies have examined the availability, price and affordability of medicines in China using the standardized method developed by World Health Organization (WHO) and Health Action International (HAI) \[[@pone.0223769.ref013], [@pone.0223769.ref016]--[@pone.0223769.ref019]\]. The results generated by these researches showed that generally the medicine price was decreasing with time but the availability was also decreasing. And the medicines' availability in public hospitals were lower than that in private pharmacies, especially generics. Among the previous studies, two focused on insulin products, and others evaluated the price and availability of general medicines which only included three oral anti-diabetic medicines (glibenclamide, gliclazide and metformin). Besides, the WHO/HAI survey manual recommended to survey only one specific strength and dosage for each medicine. As there were many strengths and dosages for each medicine in China, using a standardized WHO/HAI method would underestimate the availability of medicines.

We have previously investigated the availability and prices of medicines in Shaanxi Province of China in different years and also in Pakistan \[[@pone.0223769.ref018]--[@pone.0223769.ref023]\], including an investigation of prices, price component, availability and affordability of insulin products in Shaanxi province as supported by WHO \[[@pone.0223769.ref019]\]. The objective of this study was to assess the price, availability and affordability of oral anti-diabetic medicines in Shaanxi Province in western China. We conducted a cross sectional survey from May to July in 2015 in Shaanxi Province using a modified WHO/HAI methodology, which included all the strengths and dosages of each medicine. To the best of our knowledge, this was the first study of its type in western China focusing on oral anti-diabetic medicines. We believed it would be helpful to government policymakers, researchers and practitioners.

Methods {#sec006}
=======

Study setting {#sec007}
-------------

Shaanxi was located in western China, with a population of 37.93 million and 11 areas in its jurisdiction, ranked 14th for GDP per capita in mainland China (31 provinces in total in the mainland) in 2015 \[[@pone.0223769.ref024]\]. Shaanxi was broadly representative of the typical health of the 12 western provinces of China, and in 2012 the Ministry of Health of China and WHO selected Shaanxi as one of the three pilot regions for the western area health initiative to explore key health issues in western China \[[@pone.0223769.ref025]\].

Sampling {#sec008}
--------

According to the WHO/HAI manual, Xi'an (the capital city of Shaanxi Province) was selected as the major urban center. An additional five areas (Yulin, Xianyang, Baoji, Shangluo and Weinan) reachable within one day's travel of Xi'an were randomly chosen.

In each survey area, we first selected the main public hospital (usually a tertiary hospital). Additional 11 public hospitals per survey area were then randomly selected three hour's drive from the main hospital. The public sector sample therefore contained 12 public hospitals (including 2 tertiary hospitals, 4 secondary hospitals and 6 primary hospitals) in each of the six survey areas, for a total of 72 public hospitals. The private sector sample was identified by selecting the private pharmacy closest to each of the selected public hospitals. In total, 72 public hospitals and 72 private pharmacies were included. Among the 72 public hospitals, 33 hospitals (all the tertiary hospitals and 21 secondary hospitals) had 15% profit margin for medicines, and 39 hospitals (all the primary hospitals and 3 secondary hospitals) had implemented zero mark-up policy.

Medicine selection {#sec009}
------------------

We focused on oral anti-diabetic medicines and excluded insulin in our survey. The reasons were two folds. Firstly, insulin was not the first choice of most patients in China. Insulin is a life-saving medicine for people with type 1 diabetes and is used to manage an increasing number of people with type 2 diabetes \[[@pone.0223769.ref026]\]. However, according to the latest National Health Service survey in China, only 15% of patients with diabetes chose insulin for treatments \[[@pone.0223769.ref027]\]. Secondly, the information of insulin (availability and price) was provided in two papers in Shaanxi and Hubei Provinces in China \[[@pone.0223769.ref013], [@pone.0223769.ref019]\]. For most research which surveyed the price and availability, only included 2 or 3 oral anti-diabetic medicines. To the best of our knowledge, currently no research provided the information of availability and price of all the oral-diabetic medicines in Shaanxi.

There were 3 oral medicines for diabetes suggested by WHO/HAI manual, including glibenclamide from the global core list, metformin and gliclazide from the regional core list. In addition to these 3 medicines, we included 5 supplementary medicines, which were selected by referring to "China guideline for type 2 diabetes (2013)" \[[@pone.0223769.ref028]\] and "Standard Therapeutic Guidelines for National Essential Drugs" \[[@pone.0223769.ref029]\]. In total, 8 medicines were selected. Of these, 6 were essential medicines, and two were not.

We identified all the dosages and strengths for each medicine used in Shaanxi Province by referring to the information provided by the provincial Food and Drug Administration, which is the official institution responsible for administration of pharmaceuticals in Shaanxi province. Finally, 31 different dosages or strengths were included for the 8 medicines, covering originator brands (OBs) and generics ([Table 1](#pone.0223769.t001){ref-type="table"}). Because the original brand of glibenclamide were not used in Shaanxi Province, we only included the generics.

10.1371/journal.pone.0223769.t001

###### Medicines selected for survey.

![](pone.0223769.t001){#pone.0223769.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                                                 Medicine type                                                                           Dosage forms and strengths
  ---------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------
  Acarbose[\*](#t001fn002){ref-type="table-fn"}        OB                                                                                      50 mg tab

                                                       Generics                                                                                50 mg tab/cap

  Glibenclamide[\*](#t001fn002){ref-type="table-fn"}   Generics                                                                                2.5 mg tab

  Gliclazide[^\#^](#t001fn003){ref-type="table-fn"}    OB                                                                                      30 mg SR tab, 80 mg tab

  Generics                                             30 mg SR tab, 80 mg tab                                                                 

  Glimepiride[\*](#t001fn002){ref-type="table-fn"}     OB                                                                                      2 mg tab

                                                       Generics                                                                                1 mg tab, 2 mg tab/cap

  Glipizide[\*](#t001fn002){ref-type="table-fn"}\      OB                                                                                      5 mg CR tab

  Generics                                             2.5 mg tab/cap, 5 mg tab/cap, 5 mg CR tab                                               

  Metformin[\*](#t001fn002){ref-type="table-fn"}\      OB                                                                                      500 mg tab, 800 mg tab

  Generics                                             250 mg tab/cap, 500 mg tab, 250 mg SR cap, 500 mg SR tab, 250 mg and 500 mg R cap/tab   

  Pioglitazone                                         OB                                                                                      15 mg tab

  Generics                                             5 mg tab, 15 mg tab/cap, 30 mg tab                                                      

  Repaglinide                                          OB                                                                                      1 mg tab, 2 mg tab

  Generics                                             0.5 mg tab, 1 mg tab, 2 mg tab                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SR: sustained release; CR: controlled release; R: retard. OB: originator brands.

\*: National essential medicine

^\#^: Provincial essential medicine

Data collection and entry {#sec010}
-------------------------

Twelve well-trained data collectors were organized in pairs to visit medicine outlets and record medicine availability and price on the day of the survey, using a standardized data collecting form ([S1 File](#pone.0223769.s001){ref-type="supplementary-material"}). For each generic, as there were many manufacturers, we only collected the price of lowest-priced generic (LPG).

Two trained graduate students entered all the survey data into the pre-programmed Excel Workbook (WHO/HAI 2015) using a double entry technique.

Statistical analysis {#sec011}
--------------------

### 1) Availability {#sec012}

The availability of each medicine was reported as the percentage of outlets in which the medicine was found on the day of data collection. If one outlet had at least a specific dosage or strength of one medicine, this medicine was denoted as available in this outlet.

The following ranges were used for describing availability: not available (availability = 0), very low (0\< availability\<30%), low (30%≤availability\<50%), fairly high (50%≤availability\< 80%), high (availability ≥80%) \[[@pone.0223769.ref030]\].

### 2) Price {#sec013}

For one medicine, if the original brand and generic had the same dosage form and strength, we compared their prices using median price variation ratio. Besides, the median price ratio (MPR) was used for evaluation if the medicine had international reference price (IRP) in the Management Sciences for Health (MSH) 2015 Price Indicator Guide \[[@pone.0223769.ref031]\]. The median price was not calculated when the medicine was present in fewer than 3 outlets. The formulation of MPR were as follows.
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### 3) Affordability {#sec014}

To assess affordability, the standard treatment for each medicine was included. If the standard treatment cost 1 day's wages or less, it was considered to be affordable. As rural and urban residents had different levels of income, we used different variables to calculate. For urban residents, we used the average daily wage of the lowest-paid unskilled government workers in Shaanxi Province, which was RMB 44.1667 (USD 7.2304) at the time of this survey \[[@pone.0223769.ref032]\]. For rural residents, we used the average daily net-income of rural residents in Shaanxi Province in 2015, which was RMB 21.8(USD 3.5688) \[[@pone.0223769.ref033]\]. The calculation process of standard treatment cost was:

$\text{The~standard~treatment~cost} = \text{the~median~price~per~mg} \times \text{daily~dose} \times \text{standard~treatment~duration}$Where, the daily dose and the standard treatment duration were converted to mgs and days, respectively. If a medicine treatment cost less than 1 day's wages or net income, we regarded its affordability as good.

We tested normality and homogeneity of variances of prices and affordability, and performed either parametric (independent *t* test or paired *t* test) or non-parametric (Mann-Whitney U test) analyses to compare the differences of those indictors between public and private sectors. All statistical analyses were conducted using SPSS 18.0 and a *p* value \<0.05 was considered as statistical significance.

Ethics {#sec015}
------

The Ethics Committee of Xi'an Jiaotong University Health Science Center (Xi'an, China) reviewed this study and stated that no formal ethics approval was required in this particular case. Oral consents were obtained from all participating organizations.

Results {#sec016}
=======

Availability {#sec017}
------------

The mean availability of OBs and generics was 34.3% and 28.7%, respectively in the public hospitals, and 44.1% and 64.4% in the private pharmacies ([Table 2](#pone.0223769.t002){ref-type="table"}). Among all the hospitals, tertiary hospitals had highest availability of both OBs and generics, wherever primary hospitals had the lowest. And hospitals with 15% mark-up for medicines had higher availability of both OBs and generics than hospitals without. In both sectors, metformin and acarbose had the highest availability among all the OBs and generics, respectively. In general, the mean availability of sampled medicines was higher in the private pharmacies than the public hospitals except the OBs of repaglinide and pioglitazone. Most of the generic medicines were more available than originator brands in both sectors, except gliclazide, acarbose and repaglinide.

10.1371/journal.pone.0223769.t002

###### Availability of anti-diabetic medicines in public hospitals and private pharmacies in Shaanxi Province, China in 2015 (%).
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                  Tertiary hospital   Secondary hospital   Primary hospital   Hospitals with mark-up   Hospitals without mark-up   All public hospitals   All private pharmacies                                             
  --------------- ------------------- -------------------- ------------------ ------------------------ --------------------------- ---------------------- ------------------------ ------ ------ ------ ------ ------ ------ ------
  Acarbose        100.0               58.3                 83.3               29.2                     47.2                        19.4                   9.1                      36.4   4.9    23.1   68.1   29.2   91.7   50.0
  Glibenclamide   /                   8.3                  /                  0                        0                           5.6                    /                        9.1    /      2.6    /      5.6    /      20.8
  Gliclazide      83.3                25.0                 58.3               45.8                     25.0                        22.2                   66.7                     36.4   23.1   25.6   45.8   30.6   83.3   75.0
  Glimepiride     50.0                58.3                 25.0               29.2                     5.6                         22.2                   36.4                     42.4   5.1    2.1    19.4   19.4   29.2   80.6
  Glipizide       16.7                50.0                 4.2                50.0                     2.8                         44.4                   9.1                      48.5   2.6    46.2   5.6    47.2   5.6    80.6
  Metformin       44.4                91.7                 58.3               100.0                    25.0                        91.7                   69.7                     97.0   20.5   92.3   44.4   94.4   81.9   97.2
  Pioglitazone    16.7                33.3                 0                  0                        0                           0                      6.1                      21.2   0      0      2.8    29.2   0      31.9
  Repaglinide     100.0               25.0                 66.7               4.2                      30.6                        0                      81.8                     12.1   30.8   0      54.2   54.2   16.7   79.2
  Mean            58.7                43.7                 42.3               32.3                     19.5                        25.7                   39.8                     37.9   12.4   24.0   34.3   28.7   44.1   64.4

/: No data for this medicine, because the original brand of glibenclamide were not used in Shaanxi Province. OBs: originator brands. Gs: generics.

In the public hospitals, the availability of six generics were low (less than 50%), and both the OB and generics of repaglinide have fairly high availability ([Table 3](#pone.0223769.t003){ref-type="table"}). In the private pharmacies, the availability of most generics were more than 50% (fairly high or high), and gliclazide, metformin and acarbose were highly available (more than 80%).

10.1371/journal.pone.0223769.t003

###### Availability rating of anti-diabetic medicines.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Availability    Public hospitals                     Private pharmacies                                             
  --------------- ------------------------------------ ------------------------------------- ------------------------ ---------------------------------
  Not available   None                                 None                                  Pioglitazone             None

  Very low        Glimepiride Glipizide Pioglitazone   Acarbose Glibenclamide Glimepiride\   Glipizide Glimepiride\   Glibenclamide
                                                       Pioglitazone                          Repaglinide              

  Low             Gliclazide Metformin                 Gliclazide Glipizide                  None                     Pioglitazone

  fairly high     Acarbose Repaglinide                 Repaglinide                           None                     Acarbose Gliclazide Repaglinide

  High            None                                 Metformin                             Acarbose\                Glimepiride Glipizide Metformin
                                                                                             Gliclazide Metformin     
  -----------------------------------------------------------------------------------------------------------------------------------------------------

OBs: originator brands. Gs: generics.

Price {#sec018}
-----

Comparing the price between OBs and LPGs, we found that the price of OB was 3.38 and 3.16 times the LPGs on average in public hospitals and private pharmacies ([Table 4](#pone.0223769.t004){ref-type="table"}). In public hospitals, the biggest difference between OB and LPGs was Glipizide (OB/LPG = 6.47), and the smallest was Acarbose (OB/LPG = 1.44). While in private pharmacies, the biggest difference between OB and LPGs was metformin (OB/LPG = 6.58), and the smallest was repaglinide (2 mg tab, OB/LGP = 1.05). Overall, the OBs of acarbose, gliclazide (80 mg tab and 30 mg SR tab), glimepiride, metformin and repaglinide (1 mg and 2 mg tab) were higher priced in public hospitals than in private pharmacies (*p*\<0.05). While for generics, except of acarbose which was higher priced in public hospitals, the other medicines were similarly priced in public and private sectors. However, taken the 9 standard treatment as a whole, the day's wages to pay for urban and rural residents, there was no significant difference between public and private sectors (*P*\>0.05).

10.1371/journal.pone.0223769.t004

###### The median price (RMB) of anti-diabetic medicines.
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  Medicines       Public hospitals   Private pharmacies   Comparison between public and private[\*](#t004fn002){ref-type="table-fn"}                                       
  --------------- ------------------ -------------------- ---------------------------------------------------------------------------- ------ ------ ------ ------ ------- -------
  Acarbose        50 mg tab          2.47                 1.71                                                                         1.44   1.77   1.40   1.26   0.000   0.000
  Glibenclamide   2.5 mg tab         /                    0.02                                                                                /      0.02                  
  Gliclazide      80 mg tab          1.24                 0.27                                                                         4.59   1.05   0.31   3.39   0.000   0.435
  Gliclazide      30 mg SR tab       1.89                 0.53                                                                         3.57   1.60   0.65   2.46   0.042   0.612
  Glimepiride     2 mg tab           5.19                 1.22                                                                         4.25   3.87   1.23   3.15   0.000   0.714
  Glipizide       5 mg CR tab        2.78                 0.43                                                                         6.47   2.64   0.45   5.87   0.064   
  Metformin       500 mg tab         1.45                 0.95                                                                         1.53   1.25   0.19   6.58   0.000   0.056
  Pioglitazone    15 mg tab          /                    /                                                                                   /      5.05                  
  Repaglinide     1 mg tab           2.47                 1.35                                                                         1.83   1.93   1.29   1.50   0.000   0.651
  Repaglinide     2 mg tab           2.80                 /                                                                                   2.27   2.17   1.05   0.000   
  Mean                                                                                                                                 3.38                 3.16           

/: No value, because when the medicine was present in fewer than 3 outlets, the median price was not calculated.

\*: *t* test or ANOVA for data with normal distribution; Mann-Whitney U tests for data with non-normal distribution

Among all these medicines, there were 3 medicines with 4 different dosage forms and strengths, which had IRPs. Comparing their median price with IRPs, the results showed that only the LGP of gliclazide (80 mg) had lower price than the IRP. The median patient price for the 4 OBs was 12.38 times the IRP in public hospitals, and 10.26 times in private pharmacies. For the 4 LPGs, the median patient price was 4.52 and 2.81 times the IRP in public hospitals and private private pharmacies, respectively. The public hospitals sold OB glimepiride at extremely high price, with 21.25 times the IRP ([Table 5](#pone.0223769.t005){ref-type="table"}).

10.1371/journal.pone.0223769.t005

###### MPRs of four anti-diabetic medicines with IRP.

![](pone.0223769.t005){#pone.0223769.t005g}

  Medicine                  Public hospitals   Private pharmacies           
  ------------------------- ------------------ -------------------- ------- ------
  Gliclazide 80 mg tab      4.16               0.90                 3.53    1.04
  Gliclazide 30 mg SR tab   9.50               2.64                 9.06    3.26
  Glimepiride 2 mg tab      21.25              5.00                 15.83   5.03
  Metformin 500 mg tab      14.60              9.55                 12.63   1.89
  Mean                      12.38              4.52                 10.26   2.81

Affordability {#sec019}
-------------

[Table 6](#pone.0223769.t006){ref-type="table"} and [Table 7](#pone.0223769.t007){ref-type="table"} showed the affordability of 9 standard treatments for diabetes in both sectors. All the OB treatments cost more than 1 day's wages except gliclazide (80 mg). If patients choose treatment with the LPGs, the medicines would be much more affordable. For example, for urban residents 1 month's treatment with glipizide controlled release (5 mg per day) purchased from public hospitals required 1.89 days' wages for the OB, but just 0.26 days' wages for its generic equivalent. The affordability of these medicines for urban residents was much better for rural residents. All the LGPs in public hospitals were much more affordable than that in private pharmacies, except acarbose and repaglinide. On the contrary, all the OBs in private pharmacies were much more affordable than that in public hospitals, except repaglinide.

10.1371/journal.pone.0223769.t006

###### Costs (RMB) of standard treatments with original brand anti-diabetic medicines.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Originators          Dosage per day\   Median price per mg   Cost for a duration   Day's wages to pay for treatment for urban residents   Day's income to pay for treatment for rural residents                                       
                       (mg)                                                                                                                                                                                                             
  -------------------- ----------------- --------------------- --------------------- ------------------------------------------------------ ------------------------------------------------------- ------ ------ ------ ------- ------ ------
  Acarbose             150               0.049                 0.035                 220.5                                                  157.5                                                   4.99   3.57   0.09   10.11   7.22   0.09

  Glibenclamide        5                 /                     /                     /                                                      /                                                       /      /      /      /              

  Gliclazide\          30                0.063                 0.0533                56.7                                                   47.97                                                   1.28   1.09   2.60   2.20           
  (30 mg)                                                                                                                                                                                                                               

  Gliclazide (80 mg)   80                0.016                 0.0131                38.4                                                   31.44                                                   0.87   0.71   1.76   1.44           

  Glimepiride          2                 2.597                 1.9334                155.82                                                 116.004                                                 3.53   2.63   7.15   5.32           

  Glipizide            5                 0.556                 0.5286                83.4                                                   79.29                                                   1.89   1.80   3.83   3.64           

  Metformin            1000              0.003                 0.002                 90                                                     60                                                      2.04   1.36   4.13   2.75           

  Pioglitazone         30                /                     /                     /                                                      /                                                       /      /      /      /              

  Repaglinide          2                 1.428                 1.667                 85.68                                                  100.02                                                  1.94   2.26   3.93   4.59           

  Mean                                   0.67                  0.61                  104.36                                                 84.60                                                   2.36   1.92          4.79    3.88   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

/: No value, the original brand medicines were not available.

\*: paired *t* tests.

10.1371/journal.pone.0223769.t007

###### Costs (RMB) of standard treatments with anti-diabetic LPGs.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Generics             Dosage per day\   Median price per mg   Cost for a duration   Day's wages to pay for treatment for urban residents   Day's income to pay for treatment for rural residents                                      
                       (mg)                                                                                                                                                                                                            
  -------------------- ----------------- --------------------- --------------------- ------------------------------------------------------ ------------------------------------------------------- ------ ------ ------ ------ ------ ------
  Acarbose             150               0.034                 0.028                 153                                                    126.0                                                   3.46   2.85   0.81   7.02   5.78   0.72

  Glibenclamide        5                 0.007                 0.008                 1.05                                                   1.2                                                     0.02   0.03   0.05   0.06          

  Gliclazide\          30                0.017                 0.021                 15.3                                                   18.9                                                    0.35   0.43   0.70   0.87          
  (30 mg)                                                                                                                                                                                                                              

  Gliclazide (80 mg)   80                0.003                 0.004                 7.2                                                    9.6                                                     0.16   0.22   0.33   0.44          

  Glimepiride          2                 0.610                 0.625                 36.6                                                   37.5                                                    0.83   0.85   1.38   1.72          

  Glipizide            5                 0.086                 0.090                 12.9                                                   13.5                                                    0.26   0.31   0.59   0.62          

  Metformin            1000              0.0005                0.001                 15.0                                                   30.0                                                    0.34   0.68   0.69   1.38          

  Pioglitazone         30                0.146                 0.162                 131.4                                                  145.8                                                   2.98   3.30   6.03   6.69          

  Repaglinide          2                 1.380                 1.327                 82.8                                                   79.62                                                   1.87   1.80   3.80   3.65          

  Mean                                   0.25                  0.25                  50.56                                                  51.35                                                   1.15   1.16          2.32   2.36   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*: paired *t* tests.

Discussion {#sec020}
==========

In the present study, we evaluated the availability, price and affordability of anti-diabetic medicines using a modified WHO/HAI methodology in Shaanxi Province, China. There were two main findings: 1) Three anti-diabetic OBs and 3 generics met the WHO's availability target (80% availability)\[[@pone.0223769.ref034]\] in private sector, and only 1 generics met this target in public sector; 2) OBs cost much more than their generic equivalents, and treatment with OBs was unaffordable, especially for rural residents.

There was enormous availability difference between public hospitals and private pharmacies. OBs had higher availability than generics in public hospitals, while opposite situation was observed in the private pharmacies. Because in China, previously the government allowed the public hospitals a 15% profit margin on drugs, which induced serious health hazards and physicians tended to over-prescribe, especially expensive medicines \[[@pone.0223769.ref024]\]. Even after 2017, this 15% mark-up was cancelled for all the public hospitals, physician in public hospitals still had higher financial incentives to prescribe expensive OBs as they can get more grey income from pharmaceutical companies \[[@pone.0223769.ref035]\]. And another possible reason could contribute to this result was that most physicians in China believed OBs had better clinical results than generics. The Chinese government has not required generic drugs to have the same quality and efficacy as the original drugs until the early of 2016. Therefore before 2016, local generics were not bioequivalent with the originators and were deemed of lower quality \[[@pone.0223769.ref036]\]. While in private pharmacies, they were more willing to provide lowest-priced generics to gain more customers because of fierce market competition. In general, the availability in the private pharmacies was better than in the public hospitals. This could be the consequence of regulation issued by Chinese Ministry of Health in 2006, which required all public health institutions should purchase one medicine with no more than two types of dosage forms for injection and oral medicines \[[@pone.0223769.ref037]\]. The difference of availability was particularly true in our survey as all the strengths and dosage forms were accounted. Using this methodology, the availability of medicines increased a lot comparing to previous studies using standard WHO/HAI method. For example, the availability of gliclazide generics evaluated by Jiang et al \[[@pone.0223769.ref023]\] was only 45% in private pharmacies, while in our study it increased to 75%.

Among all these medicines, the availability of glibenclamide was especially low. The OB of glibenclamide was not available, and the availability of its generics was very low in both sectors. This was similar with the result of Guan et al. \[[@pone.0223769.ref038]\]. As we talked with several clinical pharmacists, they told us that currently the overall use of sulfonylureas was relatively low as the sulfonylurea agents had a higher risk of hypoglycemic reactions comparing with other oral hypoglycemic medicines, and they hardly used glibenclamide, as it was a long-acting sulfonylurea agent which had more adverse effects.

For OBs, we found that the price was higher in public hospitals than in private pharmacies. But for generics, there was no significant difference between different sectors. We speculated that this finding occurred because most OBs had higher availability at hospitals with 15% mark-up than hospitals without mark-ups. In addition, intensified competition also made the private pharmacies charge less.

The affordability of OBs was poor. Although the affordability of LPGs was better, more than half of these medicines were not affordable for rural residents. Especially for acarbose, repaglinide and pioglitazone, even the urban residents cannot afford the treatment with these LPGs. But even worse, the availability of these LPGs in the public sector was poor, and the majority of patients must purchase medicine from the private pharmacies or buy more expensive brand-name drugs. Moreover, under current medical insurance scheme, mostly patients had to pay their own expenses if they bought medicines from private pharmacies. These factors can increase the economic burden for patients.

Compared with insulin products, the oral anti-diabetic medicines had lower availability but higher affordability. Li et al.'s \[[@pone.0223769.ref019]\] reported the availability and affordability of insulin in Shaanxi province, all three kinds of insulin products (prandial, basal and premixed insulin) had a 100% availability in public hospitals, and a fairly high availability in private sector ranging from 62.5% to 68.8%, while in our survey even the highest availability (generics in private pharmacy) was only 64.4%. For the affordability, the insulin products would cost 3.5 to 17.1 days' wage of lowest-paid government worker (urban residents) in Shaanxi, while even the oral anti-diabetic OBs just cost 0.71 to 4.99 days' wage for urban residents. Another study about insulin in Hubei province \[[@pone.0223769.ref016]\] generated similar results as Li et al. The big price gap between insulin products and oral anti-diabetics maybe was one important reason why there was only 15% of patients with diabetes choosing insulin for treatments

Compared with general medicines, the availability of oral anti-diabetic in our survey was higher. Fang et al.\[[@pone.0223769.ref018]\] survey 50 medicines in Shaanxi in 2012, the availability of the 8 oral anti-diabetic OBs were 3.94 and 2.77 times of the availability of OBs of the 50 general medicines in public and private sectors, respectively; 1.4 and 1.82 times for generics in public and private sectors.

This study had some limitations. First, the availability of anti-diabetic medicines was measured at specific facilities on the day of the survey. The facilities surveyed may normally have a product in stock, but they may have run out of the medicine on the day of data collection. We may not accurately capture the availability of medicines. Secondly, our study was limited to one province only. Therefore the results may not be generalizable to the whole country. Thirdly, the affordability was calculated for single medicine for diabetes, whereas patients may take multi-medicine at a time. So, the affordability may be overestimated.

Conclusion {#sec021}
==========

The availability of most generics was fairly high in private pharmacies, but low in public hospitals. In both sectors most generics were more available than OBs. The high prices of OBs had severely influenced the affordability of medicines, especially for the rural residents. An effective policy should be initiated to ensure patients had better access to more affordable anti-diabetic medicines.

Supporting information {#sec022}
======================

###### Data collecting form.

(DOCX)

###### 

Click here for additional data file.

We appreciate the cooperation and participation of the pharmacists and other staff at the medicine outlets where data was collected.

10.1371/journal.pone.0223769.r001
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Reviewer \#1: The study assesses availability and prices of oral anti-diabetic medicines in Shaanxi province in Western China, using a slightly modified WHO/HAI methodology to measure availability and prices of essential medicines.

It is a sound research, that includes a large basket of survey points (public hospitals and private pharmacies). It is based on an established methodology whose further development is justified. The presented evidence on availability and prices of medicines in different parts of the world is appreciated and needed.

The paper is well written in standard English and meets the requirements of a scientific study. I congratulate the author on this article.

I see one major limitation:

1\. The study did not include insulin. This is only briefly mentioned in the limitations but no reason is provided. It is reported that treatment with insulin was "effective and safe" (in China or the studied province?) but no evidence (reference) is provided to justify this statement. I would like to see an explicit mentioning of the exclusion of insulin from the study in the methods section, including an explanation why authors decided to do so.

In order to improve the quality of the article, I recommend considering the following suggestions:

2\. As the article is intended for an international readership, some background information on the Chinese health and pharmaceutical system is missing. This would allow the readers putting the findings into context. There is some information provided in the discussion, e.g.

\- financial incentives (lines 239 ff.)

\- the issue with the mark-ups, mentioned in brackets (lines 257ff.)

\- patients purchasing out-of-pocket medicines and the reference to the medical insurance scheme (lines 264ff.)

It would be appreciated if these pieces of information were nicely presented in the introduction. Also, it would be helpful for readers to understand the supply/dispensing channels. For instance, can outpatients get prescriptions from (public) hospitals?

3\. I would like to see the findings of this study discussed in the light of current literature, in particular against the backdrop of other WHO/HAI studies performed on China (even if they were on other medicines) as well as of other price studies on diabetes medicines. I do not consider references 25 and 26 sufficient. In this respect, it is a pity that insulins were excluded from the study since reference studies on diabetes medication, such as the ACCISS (Addressing the Challenges and Constraints of Insulin Sources and Supply) project undertaken by HAI, usually refer to insulins.

4\. The study was performed in one province of China. This should also be stated explicitly in line 107 (as it is done in the abstract). It is totally fine to limit the scope of the study to one province. However, it would be appreciated to add some background information on this province, including an assessment whether, or not, this province is representative for China.

5\. Throughout the article, the terminology "lowest-priced generic" / LPG, based on the WHO/HAI methodology, is used. In the WHO/HAI context, this is correct since the methodology only includes a specific dosage and strength of a medicine. However, the authors further developed the methodology to include all dosages and strengths. As such, I would not talk of LPGs in the section on availability but simply of generics. The term LPG works, however, well for the sections on the prices.

6\. There are some inconsistencies in the text, sometimes OBs are mentioned first followed by generics, and in other parts (see also the order of Tables 6 and 7) it is the other way round. This should be harmonised.

7\. More out of curiosity: I see that the price survey was performed in Q2/2015. Why was the paper submitted only in 2019?

Further specific comments:

8\. Lines 74-75: "Although an additional diagnostic criterion was included after 2010" → this is not fully clear, kindly rephrase/explain

9\. Lines 82-83: "its complications" → this is not fully clear, kindly rephrase

10\. Line 102: "the WHO/HAI survey manual only surveyed one ..." → it is suggested to rephrase into "the WHO/HAI survey manual recommends to survey only one ..." (since the manual does not survey)

11\. Line 131: "we found" → "we identified"?

12\. Line 132: What is the role of the provincial Food and Drug Administration? Is it the marketing authorisation authority (as the FDA in the US)? Does marketing authorisation differ between the provinces of China?

13\. Line 144: "using a standardized data collecting form" → kindly mention that this is the form provided by the WHO/HAI manual (if you used this form), and could you provide an English translated version of the form (or a summary) in the Supplementary Materials

14\. Line 179: "participated" → "participating"

15\. Line 199: "/: No data" -- there is no missing data in the table

16\. Line 209, line 227 and line 228: RMB -- this should probably read "MPR"?

17\. Consistencies in having a blank and not having a blank between a figure and "mg"

18\. Line 228: first row of Table 7 should be "originator", not generic

19\. Lines 233 and 278: "the availability of anti-diabetic medicines was not optimistic": I strongly suggest rephrasing. In this respect, it would be good to set the information in the context to some baseline indicator, such as WHO's 80% availability of affordable essential medicines, including generics, to treat major non-communicable diseases (NCDs), in the public and private sectors of countries by 2025 (see also: Ewen M, Zweekhorst M, Regeer B, Laing R. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases. PLOS ONE. 2017;12(2):e0171284).

Reviewer \#2: This is a normal evaluation study on medicine access. Basically it was conducted based on WHO/HAI methodology and adjusted according to China\'s national conditions. The findings are relatively reliable. However, still some minor revisions should be made.

Introduction

1.Line 96-97 Please explained the reasons why many patients do not receive diabetes treatmen in more detail.

2.Line 100-102 The literature analyses could be updated. A research artical published in 2018 included 20 antidiabetic drugs in Huibei, China. So the statement "this was the first study of its type in China focusing on oral anti-diabetic medicines" in Line 109 is not exactly accurate.

Results

3.The sector or drug category comparisons should be based on some statistical tests, includuing t test and etal, especially for Table 4-7.

Discussion

4.Line 238 The preference for OBs due to financial incentives could be an import factor, but it should not be the only one. This finding should be discussed more.

5.As for this speculation in 256-258, some analysis can be added in the results section, such as in this survey how many OBs were availability at hospitals with 15% mark-up than hospitals

6.Line 265-266 The availability of LPGs in the public sector was poor, and the majority of patients must purchase medicine from the private pharmacies or buy more expensive brand-name drugs, which could increase the economic burden for patients. However, the Table 4 and 5 showed the median price of anti-diabetic medicines in private pharmacies was lower than public hospitals.

7.Line 267 The China\'s new health insurance policy for chronic diseases such as diabetes could be more conducive to improve affordability.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Sabine Vogler

Reviewer \#2: No
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Response to Reviewers

Reviewer \#1

The study assesses availability and prices of oral anti-diabetic medicines in Shaanxi province in Western China, using a slightly modified WHO/HAI methodology to measure availability and prices of essential medicines.

It is a sound research that includes a large basket of survey points (public hospitals and private pharmacies). It is based on an established methodology whose further development is justified. The presented evidence on availability and prices of medicines in different parts of the world is appreciated and needed.

The paper is well written in standard English and meets the requirements of a scientific study. I congratulate the author on this article.

Response: Thanks for your valuable comments!

I see one major limitation:

1\. The study did not include insulin. This is only briefly mentioned in the limitations but no reason is provided. It is reported that treatment with insulin was "effective and safe" (in China or the studied province?) but no evidence (reference) is provided to justify this statement. I would like to see an explicit mentioning of the exclusion of insulin from the study in the methods section, including an explanation why authors decided to do so.

Response: Thanks for your comments! We added the reason for choosing the oral medicines in "Medicine Selection" in part of "Methods" like following:

"We focused on oral anti-diabetic medicines and excluded insulin in our survey. The reasons were two folds. Firstly, insulin was not the first choice of most patients in China. Insulin is a life-saving medicine for people with type 1 diabetes and is used to manage an increasing number of people with type 2 diabetes \[26\]. However, according to the latest National Health Service survey in China, only 15% of patients with diabetes chose insulin for treatments \[27\]. Secondly, the information of insulin (availability and price) was provided in two papers in Shaanxi and Hubei Provinces in China \[13, 19\]. For most research which surveyed the price and availability, only included 2 or 3 oral anti-diabetic medicines. To the best of our knowledge, currently no research provided the information of availability and price of all the oral-diabetic medicines in Shaanxi."

In order to improve the quality of the article, I recommend considering the following suggestions:

2\. As the article is intended for an international readership, some background information on the Chinese health and pharmaceutical system is missing. This would allow the readers putting the findings into context. There is some information provided in the discussion, e.g.

\- financial incentives (lines 239 ff.)

\- the issue with the mark-ups, mentioned in brackets (lines 257ff.)

\- patients purchasing out-of-pocket medicines and the reference to the medical insurance scheme (lines 264ff.)

It would be appreciated if these pieces of information were nicely presented in the introduction. Also, it would be helpful for readers to understand the supply/dispensing channels. For instance, can outpatients get prescriptions from (public) hospitals?

Response: Thanks for your comments! We rewrote the introduction and added more information about the patients purchasing medicines and the medical insurance scheme like following:

"In China, patients can obtain prescription medicines from hospitals, primary care institutions, and private pharmacies with a prescription from a physician \[13\]. Although more than 95% of Chinese people were covered by social health insurance \[14\], mostly only inpatient expenditures can be refunded. In recent years, the health insurance started to consider outpatient reimbursement for chronic diseases. However, only essential medicines purchased from specific pharmacies (usually one patient can specify two public hospitals and one private pharmacy) can be reimbursed \[15\]. In China, majority of the essential medicines were generics. Therefore, for patients with diabetes, lower availability of essential anti-diabetic generics, especially in public hospitals, meant higher out-of-pocket payment, which would make them unaffordable. "

To make it naturally, we added the financial incentives and issue with mark-ups in the discussion part as following:

"There was enormous availability difference between public hospitals and private pharmacies. OBs had higher availability than generics in public hospitals, while opposite situation was observed in the private pharmacies. Because in China, previously the government allowed the public hospitals a 15% profit margin on drugs, which induced serious health hazards and physicians tended to over-prescribe, especially expensive medicines \[24\]. Even after 2017, this 15% mark-up was cancelled for all the public hospitals, physician in public hospitals still had higher financial incentives to prescribe expensive OBs as they can get more grey income from pharmaceutical companies \[35\]. And another possible reason could contribute to this result was ......."

3\. I would like to see the findings of this study discussed in the light of current literature, in particular against the backdrop of other WHO/HAI studies performed on China (even if they were on other medicines) as well as of other price studies on diabetes medicines. I do not consider references 25 and 26 sufficient. In this respect, it is a pity that insulins were excluded from the study since reference studies on diabetes medication, such as the ACCISS (Addressing the Challenges and Constraints of Insulin Sources and Supply) project undertaken by HAI, usually refer to insulins.

Response: Thanks for your comments! We rewrote the discussion and compared our results with previous studies as following:

"Compared with insulin products, the oral anti-diabetic medicines had lower availability but higher affordability. Li et al.'s \[19\] reported the availability and affordability of insulin in Shaanxi province, all three kinds of insulin products (prandial, basal and premixed insulin) had a 100% availability in public hospitals, and a fairly high availability in private sector ranging from 62.5% to 68.8%, while in our survey even the highest availability (generics in private pharmacy) was only 64.4%. For the affordability, the insulin products would cost 3.5 to 17.1 days' wage of lowest-paid government worker (urban residents) in Shaanxi, while even the oral anti-diabetic OBs just cost 0.71 to 4.99 days' wage for urban residents. Another study about insulin in Hubei province \[16\] generated similar results as Li et al. The big price gap between insulin products and oral anti-diabetics maybe was one important reason why there was only 15% of patients with diabetes choosing insulin for treatments.

Compared with general medicines, the availability of oral anti-diabetic in our survey was higher. Fang et al.\[18\] survey 50 medicines in Shaanxi in 2012, the availability of the 8 oral anti-diabetic OBs were 3.94 and 2.77 times of the availability of OBs of the 50 general medicines in public and private sectors, respectively; 1.4 and 1.82 times for generics in public and private sectors. "

4\. The study was performed in one province of China. This should also be stated explicitly in line 107 (as it is done in the abstract). It is totally fine to limit the scope of the study to one province. However, it would be appreciated to add some background information on this province, including an assessment whether, or not, this province is representative for China.

Response: Thanks for your comments! We modified according to your suggestion in the end of the background and also in the methods part as following:

In line 107, we changed to "The objective of this study was to assess the price, availability and affordability of oral anti-diabetic medicines in Shaanxi Province in western China." (Line 121 in the new version)

In methods part, we added "study setting", and introduced the Shaanxi briefly as:

"Shaanxi was located in western China, with a population of 37.93 million and 11 areas in its jurisdiction, ranked 14th for GDP per capita in mainland China (31 provinces in total in the mainland) in 2015 \[24\]. Shaanxi was broadly representative of the typical health of the 12 western provinces of China, and in 2012 the Ministry of Health of China and WHO selected Shaanxi as one of the three pilot regions for the western area health initiative to explore key health issues in western China \[25\].."

5\. Throughout the article, the terminology "lowest-priced generic" / LPG, based on the WHO/HAI methodology, is used. In the WHO/HAI context, this is correct since the methodology only includes a specific dosage and strength of a medicine. However, the authors further developed the methodology to include all dosages and strengths. As such, I would not talk of LPGs in the section on availability but simply of generics. The term LPG works, however, well for the sections on the prices.

Response: Thanks for your comments! We changed the expression of LPG to generics in availability (including abstract, results and discussion parts).

6\. There are some inconsistencies in the text, sometimes OBs are mentioned first followed by generics, and in other parts (see also the order of Tables 6 and 7) it is the other way round. This should be harmonised.

Response: Thanks for your comments! We went through the paper and changed the inconsistencies according to your suggestion.

7\. More out of curiosity: I see that the price survey was performed in Q2/2015. Why was the paper submitted only in 2019?

Response: Thanks for your question! We submitted this paper to one journal in the early of 2017 which rejected us in the beginning of 2018 because they did not find any reviewer; then we submitted to another journal, after 6 months without no response, we withdrew it and then submitted to Plos One.

Further specific comments:

8\. Lines 74-75: "Although an additional diagnostic criterion was included after 2010" → this is not fully clear, kindly rephrase/explain

Response: Thanks for your comments! We explained it in the new version like this: "Although an additional diagnostic criterion HbA1c (glycated hemoglobinA1c, concentration of 6.5% or higher) was included after 2010".

9\. Lines 82-83: "its complications" → this is not fully clear, kindly rephrase

Response: Thanks for your comments! We explained it in the new version:

"Health expenditure related to diabetes and its complications (such as periodontal disease, vision loss, diabetic foot, end-stage renal disease and cardiovascular disease, etc.)"

10\. Line 102: "the WHO/HAI survey manual only surveyed one ..." → it is suggested to rephrase into "the WHO/HAI survey manual recommends to survey only one ..." (since the manual does not survey)

Response: Thanks for your comments, we modified the paper according to your suggestion.

11\. Line 131: "we found" → "we identified"?

Response: Thanks for your comments, we changed the expression according to your suggestion.

12\. Line 132: What is the role of the provincial Food and Drug Administration? Is it the marketing authorisation authority (as the FDA in the US)? Does marketing authorisation differ between the provinces of China?

Response: Similar with FDA in the USA, the State Food and Drug Administration in China (SFDA) is responsible for the supervision and administration of registration of pharmaceuticals, medical devices, and to develop national standards for pharmaceuticals, medical devices. The provincial Food and Drug Administration is responsible for administration of pharmaceuticals in province. The responsibility of Food and Drug Administration in different provinces is the same.

We added an explanation following the appearance of provincial Food and Drug Administration as following: "We identified all the dosages and strengths for each medicine used in Shaanxi Province by referring to the information provided by the provincial Food and Drug Administration ,which is the official institution responsible for administration of pharmaceuticals in Shaanxi province"

13\. Line 144: "using a standardized data collecting form" → kindly mention that this is the form provided by the WHO/HAI manual (if you used this form), and could you provide an English translated version of the form (or a summary) in the Supplementary Materials.

Response: Thanks for your suggestion! We uploaded an English version of data collecting form in the supplementary materials as suggested.

14\. Line 179: "participated" → "participating"

Response: Thanks for your comments, we corrected the error.

15\. Line 199: "/: No data" -- there is no missing data in the table

Response: Thanks for your comments! We are sorry for our mistake, and corrected the error in the new version.

16\. Line 209, line 227 and line 228: RMB -- this should probably read "MPR"?

Response: Thanks for your comments! In the three places, there should be RMB, it is the official currency of China. Here it meant that the median price in RMB of each drug. To make it more understandable, we also mentioned the exchange rate of USD to RMB in the affordability part of "Statistical Analysis".

17\. Consistencies in having a blank and not having a blank between a figure and "mg"

Response: Thanks for your comments! We went through the paper and made it consistent according to your suggestion.

18\. Line 228: first row of Table 7 should be "originator", not generic

Response: Thanks for your comments! We are sorry for our mistake, and corrected the error in the new version.

19\. Lines 233 and 278: "the availability of anti-diabetic medicines was not optimistic": I strongly suggest rephrasing. In this respect, it would be good to set the information in the context to some baseline indicator, such as WHO's 80% availability of affordable essential medicines, including generics, to treat major non-communicable diseases (NCDs), in the public and private sectors of countries by 2025 (see also: Ewen M, Zweekhorst M, Regeer B, Laing R. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases. PLOS ONE. 2017;12(2):e0171284).

Response: Thanks for your comments! We referred this paper, and changed the expression to "There were two main findings: 1) Three anti-diabetic OBs and 3 generics met the WHO's availability target (80% availability)\[34\] in private sector, and only 1 generics met this target in public sector".

Reviewer \#2

This is a normal evaluation study on medicine access. Basically it was conducted based on WHO/HAI methodology and adjusted according to China\'s national conditions. The findings are relatively reliable. However, still some minor revisions should be made.

Introduction

1.Line 96-97 Please explained the reasons why many patients do not receive diabetes treatment in more detail.

Response: Thanks for your comments. For patients do not receive diabetes treatments, we think there are two most important reasons: 1) not aware of their condition (as reported by one article published in JAMA, only 30.1% were aware of their condition. 2) poor availability and lack of affordability of anti-diabetic medicines. As in this paper we only focused on medicines, we modified the expression in the article.

2\. Line 100-102 The literature analyses could be updated. A research article published in 2018 included 20 antidiabetic drugs in Huibei, China. So the statement "this was the first study of its type in China focusing on oral anti-diabetic medicines" in Line 109 is not exactly accurate.

Response: Thanks for your comments. We searched Pubmed and did not found such kind of paper in international journals. But in local journals, we found several in other provinces. Therefore, we updated the literature and to make it accurate, we changed the statement to "To the best of our knowledge, this was the first study of its type in western China focusing on oral anti-diabetic medicines."

Results

3.The sector or drug category comparisons should be based on some statistical tests, including t test and etal, especially for Table 4-7.

Response: Thanks for your comments! We added statistical test in Table 4 for each OB and LPG, comparing the price between public hospitals and private pharmacies. As for Table 5, there were median price rations of only four medicines, we thought it would not be that suitable for statistical tests. Table 6-7 showed the affordability of standard treatments for diabetes, we performed paired t test (each medicine in public and private sectors) for the 9 medicines.

Discussion

4.Line 238 The preference for OBs due to financial incentives could be an import factor, but it should not be the only one. This finding should be discussed more.

Response: Thanks for your comments. There are many reasons for physicians' preference for OBs. In the new version, we modified this part and provided another one important reason as following:

"There was enormous availability difference between public hospitals and private pharmacies. OBs had higher availability than generics in public hospitals, while opposite situation was observed in the private pharmacies. Because in China, previously the government allowed the public hospitals a 15% profit margin on drugs, which induced serious health hazards and physicians tended to over-prescribe, especially expensive medicines \[24\]. Even after 2017, this 15% mark-up was cancelled for all the public hospitals, physician in public hospitals still had higher financial incentives to prescribe expensive OBs as they can get more grey income from pharmaceutical companies \[35\]. And another possible reason could contribute to this result was that most physicians in China believed OBs had better clinical results than generics. The Chinese government has not required generic drugs to have the same quality and efficacy as the original drugs until the early of 2016. Therefore before 2016, local generics were not bioequivalent with the originators and were deemed of lower quality \[36\]."

5.As for this speculation in 256-258, some analysis can be added in the results section, such as in this survey how many OBs were availability at hospitals with 15% mark-up than hospitals

Response: Thanks for your comments! We added this results in Table 2 columns "Hospitals with mark-up" and "Hospitals without mark-up". The results showed that hospitals with 15% mark-up for medicines had higher availability of both OBs and generics than hospitals without 15% mark-up.

6\. Line 265-266 The availability of LPGs in the public sector was poor, and the majority of patients must purchase medicine from the private pharmacies or buy more expensive brand-name drugs, which could increase the economic burden for patients. However, the Table 4 and 5 showed the median price of anti-diabetic medicines in private pharmacies was lower than public hospitals.

Response: Thanks for your comments. As under current medical insurance scheme, mostly patients had to pay their own expenses if they bought medicines from private pharmacies. That is why we said purchasing from private pharmacies could increase the economic burden for patients. We added some background information in the introduction and also added a sentence for explanation in this paragraph in the new version to make it easier to understand.

In the Background: "Although more than 95% of Chinese people were covered by social health insurance \[14\], mostly only inpatient expenditures can be refunded. In recent years, the health insurance started to consider outpatient reimbursement for chronic diseases. However, only essential medicines purchased from specific pharmacies (usually one patient can specify two public hospitals and one private pharmacy) can be reimbursed \[15\]. In China, majority of the essential medicines were generics. Therefore, for patients with diabetes, lower availability of essential anti-diabetic generics, especially in public hospitals, meant higher out-of-pocket payment, which would make them unaffordable."

In the discussion: "The affordability of OBs was poor. Although the affordability of LPGs was better, more than half of these medicines were not affordable for rural residents. Especially for acarbose, repaglinide and pioglitazone, even the urban residents cannot afford the treatment with these LPGs. But even worse, the availability of these LPGs in the public sector was poor, and the majority of patients must purchase medicine from the private pharmacies or buy more expensive brand-name drugs. Moreover, under current medical insurance scheme, mostly patients had to pay their own expenses if they bought medicines from private pharmacies. These factors can increase the economic burden for patients."

7.Line 267 The China\'s new health insurance policy for chronic diseases such as diabetes could be more conducive to improve affordability.

Response: Thanks for your valuable comments! We added some information about health insurance policy for chronic diseases in part of "Introduction". And we modified our expression in discussion.

Additional Editor Comments:

In addition to the points raised by the reviewers, please add a sentence or paragraph in the introduction section citing ALL your previous publications on medicine availablity, prices and affordability in China, in Pakistan (and possibly in further countries), e.g.: \"We have previously investigated the availablity and prices of medicines in different parts of China and in other countries (citations), including an investigation of prices, availability and affordability of insulin products in Shaanxi province (citation).\"

I would have preferred if you had combined your previous data on insulin (Trop Med Int Health. 2019), and your current data on other antidiabetic medicines (both from Shaanxi province), into a single publication. I advise you to combine such data in future, in order to avoid the impression that you attempt to make as many publications as possible out of a limited amount of data.

Response: Thanks for your valuable comments and suggestion! We added our previous publications on this topic in the introduction as "We have previously investigated the availability and prices of medicines in Shaanxi Province of China in different years and also in Pakistan \[18-23\], including an investigation of prices, price component, availability and affordability of insulin products in Shaanxi province as supported by WHO \[19\]. The objective of this study".

Thanks for you great suggestion! We will consider this in the future. Because the survey about insulin and the oral-diabetic medicines were implemented by different students, they belong to different projects. The insulin survey was organized by WHO, included small number of hospitals and pharmacies, and also focused on the price component part. The survey for oral-diabetic medicines only considered price and availability, but more outlets were included. We also compared the results of oral-diabetic medicines and insulin in discussion part.

10.1371/journal.pone.0223769.r003
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